830 WINTER STREET, WALTHAM, MA
Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
News, Articles of Incorporation
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Earnings Release
Annual Report to Security Holders
Changes in Board, Management or Compensation
Q2
Q1
FY 2024
Q3
FY 2023 amended
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
SEC Staff Correspondence
Correspondence
Submission Upload